Vaxart to Present Research on Second-Generation Norovirus Oral Pill Vaccine Candidate at IDWeek 2025

Core Insights - Vaxart, Inc. is presenting research on its second-generation norovirus oral pill vaccine candidate at IDWeek 2025, highlighting advancements in its vaccine development efforts [1][2] Company Overview - Vaxart is a clinical-stage biotechnology company focused on developing oral recombinant vaccines using a proprietary delivery platform [2] - The company's vaccines are designed to be administered in pill form, which can be stored and shipped without refrigeration, thus eliminating the risk of needle-stick injuries [2] - Vaxart's current development programs include vaccines targeting coronavirus, norovirus, influenza, and a therapeutic vaccine for human papillomavirus (HPV) [2] - The company has filed broad domestic and international patent applications for its proprietary technology related to oral vaccination using adenovirus and TLR3 agonists [2] Presentation Details - The presentation at IDWeek 2025 will feature an open-label Phase 1 clinical trial demonstrating improved immune responses to norovirus strains GI.1 and GII.4 from a next-generation oral bivalent vaccine candidate [2] - The session is scheduled for October 20, 2025, from 1:45 PM to 3:00 PM ET at the Georgia World Congress Center in Atlanta [2]